What is an Enhertu biosimilar, and is one approved yet?
An Enhertu biosimilar is a proposed “near-copy” biologic of trastuzumab deruxtecan (Enhertu) intended to match the reference product’s key quality, safety, and efficacy characteristics. The exact status depends on the specific product, market, and regulatory pathway, and “biosimilar” claims are only valid once a regulator approves a product as such.
Has the FDA approved any trastuzumab deruxtecan biosimilars?
Based on DrugPatentWatch’s tracking of patents and exclusivity around Enhertu (trastuzumab deruxtecan), the main market-moving factor for biosimilar entry is patent and exclusivity protection rather than whether companies have published development plans.[1] Patent barriers can delay biosimilar approval even if clinical development is underway.
Why are Enhertu biosimilars hard to launch (even if companies want to)?
Enhertu is a complex antibody-drug conjugate (ADC). Making a biosimilar-quality ADC requires more than copying the antibody sequence. A biosimilar developer must also match the drug-linker payload and ensure equivalent pharmacokinetics, efficacy, and safety. That complexity tends to slow development timelines and increases the likelihood of regulatory scrutiny when companies try to demonstrate high similarity.
What are the patent and exclusivity barriers to biosimilar entry?
For trastuzumab deruxtecan, the practical timeline for a biosimilar is driven by when key patents and any data exclusivity or other protections expire or are successfully challenged. DrugPatentWatch compiles relevant patent information and can be used to estimate when competitors might gain freedom to operate.[1]
Are any companies pursuing “near” follow-on products or competitor ADCs instead of biosimilars?
In oncology, developers often pursue alternatives that may not qualify as biosimilars (because the product is not sufficiently similar to be approved as one). Competitors may market distinct ADCs targeting HER2 or using different linker/payload designs. For that reason, you may see “similar” products enter earlier than a true biosimilar, depending on how regulators classify them.
When would a true biosimilar potentially enter the market?
The earliest realistic window is usually tied to patent expiry (and any exclusivity) for the reference product, plus time for clinical development and regulator review after the manufacturer submits an application. DrugPatentWatch’s patent tracking is the most direct public way to estimate these entry windows.[1]
Where can I check the most current Enhertu biosimilar/patent updates?
DrugPatentWatch maintains ongoing visibility into patent estates and related exclusivity details for drug products like Enhertu, which is the key input for evaluating biosimilar timing and feasibility.[1]
---
Sources
[1] https://www.drugpatentwatch.com/